Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jonathan Kell

Showing results (21-30 of 26) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 26 results.
Blood|August 28, 2009
Phase 3 randomized, placebo-controlled, double-blind study of high-dose continuous infusion cytarabine alone or with laromustine (VNP40101M) in patients with acute myeloid leukemia in first relapseFrancis Giles, Norbert Vey, Daniel DeAngelo, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 14, 2010
European development of clofarabine as treatment for older patients with acute myeloid leukemia considered unsuitable for intensive chemotherapyAlan K Burnett, Nigel H Russell, Jonathan Kell, et al.
Frontiers in Pharmacology|November 16, 2020
Reliability of a Novel Hematological Malignancy Specific Patient-Reported Outcome Measure: HM-PROPushpendra Goswami, Esther N Oliva, Tatyana Ionova, et al.
Frontiers in Pharmacology|October 5, 2020
Hematological Malignancy Specific Patient-Reported Outcome Measure (HM-PRO): Construct Validity StudyPushpendra Goswami, Esther N Oliva, Tatyana Ionova, et al.
The Lancet. Oncology|September 19, 2015
Arsenic trioxide and all-trans retinoic acid treatment for acute promyelocytic leukaemia in all risk groups (AML17): results of a randomised, controlled, phase 3 trialAlan K Burnett, Nigel H Russell, Robert K Hills, et al.
Journal of Comparative Effectiveness Research|May 1, 2019
Paper and electronic versions of HM-PRO, a novel patient-reported outcome measure for hematology: an equivalence studyPushpendra Goswami, Esther N Oliva, Tatyana Ionova, et al.
Pageof 3

Showing results (21-30 of 26) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 26 results.
Blood|August 28, 2009
Phase 3 randomized, placebo-controlled, double-blind study of high-dose continuous infusion cytarabine alone or with laromustine (VNP40101M) in patients with acute myeloid leukemia in first relapseFrancis Giles, Norbert Vey, Daniel DeAngelo, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 14, 2010
European development of clofarabine as treatment for older patients with acute myeloid leukemia considered unsuitable for intensive chemotherapyAlan K Burnett, Nigel H Russell, Jonathan Kell, et al.
Frontiers in Pharmacology|November 16, 2020
Reliability of a Novel Hematological Malignancy Specific Patient-Reported Outcome Measure: HM-PROPushpendra Goswami, Esther N Oliva, Tatyana Ionova, et al.
Frontiers in Pharmacology|October 5, 2020
Hematological Malignancy Specific Patient-Reported Outcome Measure (HM-PRO): Construct Validity StudyPushpendra Goswami, Esther N Oliva, Tatyana Ionova, et al.
The Lancet. Oncology|September 19, 2015
Arsenic trioxide and all-trans retinoic acid treatment for acute promyelocytic leukaemia in all risk groups (AML17): results of a randomised, controlled, phase 3 trialAlan K Burnett, Nigel H Russell, Robert K Hills, et al.
Journal of Comparative Effectiveness Research|May 1, 2019
Paper and electronic versions of HM-PRO, a novel patient-reported outcome measure for hematology: an equivalence studyPushpendra Goswami, Esther N Oliva, Tatyana Ionova, et al.
Pageof 3